AbbVie (NYSE:ABBV) reported a Phase 3 win as epcoritamab+lenalidomide met EPCORE DLBCL‑14's primary endpoint with strong PFS HRs (0.40 U.S., 0.44 ex‑U.S.) and expected safety, while the company paid Nxera $10M, lifting 2022 neuro R&D milestones to $40M amid up to $1.2B more possible.
Previous Week Recap
- Epcoritamab+Lenalidomide PFS Benefit: AbbVie said epcoritamab+lenalidomide met Phase 3 EPCORE DLBCL‑4 primary endpoint in relapsed/refractory DLBCL, showing PFS HR 0.40 (U.S.) and 0.44 (ex-U.S.); safety consistent with known profiles.
- Nxera Milestone Payment Reaches $10M: AbbVie paid Nxera $10M on June 30, 2026 for a fourth R&D milestone in their 2022 neuro drug-discovery deal, raising total milestone payouts to $40M; deal holds up to $1.2B more plus royalties.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.